Press Release - November 12, 2014
Heidelberg, Germany, November 12, 2014 – Affimed Therapeutics (Nasdaq: AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at Jefferies Global Healthcare Conference – London, to be held November 19-20, 2014.
Dr. Hoess’ presentation will take place November 20, 4:20-5:00 p.m. (GMT).
To access a simultaneous webcast of Mr. Hoess’ presentation online, log on to http://wsw.com/webcast/jeff86/afmd .
A replay of the webcast will be available from Affimed’s website for 30 days following the conference. Mr. Hoess’ presentation will be available for download in PDF format immediately following the conference presentation.
Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.
Adi Hoess, CEO
Phone: +49 6221 65307-0